American journal of preventive cardiology最新文献

{"title":"Cancer, genetic susceptibility and risk of coronary artery disease: A prospective study","authors":"Yidan Wang ,&nbsp;Shan Zhong ,&nbsp;Na Sun ,&nbsp;Yunfei Wu ,&nbsp;Jun Lyu ,&nbsp;Minghui Piao ,&nbsp;Wenbo Qu ,&nbsp;Xueyu Wang ,&nbsp;Wenjun Ni ,&nbsp;Xia Gu ,&nbsp;Tianshu Han ,&nbsp;Jinwei Tian","doi":"10.1016/j.ajpc.2024.100926","DOIUrl":"10.1016/j.ajpc.2024.100926","url":null,"abstract":"<div><h3>Objective</h3><div>Cancer survivors have an increased risk of developing coronary artery disease (CAD). We introduce CAD polygenic risk scores (PRS) and examine associations with cancer status on CAD outcomes.</div></div><div><h3>Methods</h3><div>From the UK Biobank, we identified cancer survivors and CAD outcomes among 464,193 CAD-free participants using linked cancer registries, hospitalizations, and death records. CAD-PRS was categorized as low (lowest tertile), intermediate (tertile 2), and high (highest tertile). Adjusted Cox models assessed the joint and interaction effects of cancer status and CAD-PRS on CAD outcomes.</div></div><div><h3>Results</h3><div>Over the follow-up (median 11.7 years), 36,332 participants developed CAD. Compared to low CAD-PRS, the hazard ratios (HRs) and 95% confidence intervals (CIs) for CAD was 1.35 (1.31–1.38) for intermediate and 1.86 (1.81–1.91) for high CAD-PRS. The HR (95% CI) for CAD in cancer survivors was 1.16 (1.13–1.19) compared to those without cancer. In the joint effect analysis, compared to participants with low CAD-PRS and no cancer, the HRs (95% CIs) for CAD were 1.37 (1.32–1.41) and 1.90 (1.84–1.96) for intermediate and high CAD-PRS without cancer, respectively. For those with cancer, the HRs (95% CIs) were 1.26 (1.19–1.33), 1.59 (1.51–1.67), and 2.13 (2.03–2.23) for low, intermediate, and high CAD-PRS, respectively. A significant multiplicative interaction (HR: 0.94, 95% CI: 0.91–0.98) was observed between CAD-PRS and cancer status on CAD. Additionally, a significant additive interaction between cancer and high CAD-PRS was found for fatal CAD.</div></div><div><h3>Conclusion</h3><div>Cancer was associated with a higher risk of CAD and may further increase the risk of CAD related to genetic factors.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100926"},"PeriodicalIF":4.3,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143101246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of neighborhood-level socioeconomic disadvantage and Life's Essential 8 in early pregnancy","authors":"Kartik K. Venkatesh ,&nbsp;William A. Grobman ,&nbsp;Xiaoning Huang ,&nbsp;Lynn M. Yee ,&nbsp;Janet Catov ,&nbsp;Hy Simhan ,&nbsp;David M. Haas ,&nbsp;Brian Mercer ,&nbsp;Uma Reddy ,&nbsp;Robert M. Silver ,&nbsp;Lisa D. Levine ,&nbsp;Judith Chung ,&nbsp;George Saade ,&nbsp;Philip Greenland ,&nbsp;C. Noel Bairey Merz ,&nbsp;Becky McNeil ,&nbsp;Sadiya S Khan","doi":"10.1016/j.ajpc.2024.100925","DOIUrl":"10.1016/j.ajpc.2024.100925","url":null,"abstract":"<div><div>We examined whether neighborhood-level socioeconomic disadvantage per the Area Deprivation Index (ADI) was associated with maternal cardiovascular health (CVH) in early pregnancy per the American Heart Association Life's Essential 8 (LE8). This is a cross-sectional analysis from the prospective Nulliparous Pregnancy Outcomes Study-Monitoring Mothers-to-Be Heart Health Study (nuMoM2b-HHS) cohort. The exposure was the ADI in tertiles (T) from least (T1) to most (T3) socioeconomic disadvantage. The outcome was the LE8 as a continuous score ranging from worst (0) to best (100) composite CVH; and included physical activity, diet quality, tobacco use, sleep quantity, body mass index, blood pressure, glucose, and lipid levels. Among 4,508 nulliparous individuals at a mean maternal age of 27.0 years (SD: 5.6) and at a mean gestational age of 11.4 weeks (SD 1.6), the mean ADI was 48.0 (SD: 30.4) and the mean LE8 was 80.3 (SD: 12.5). Pregnant individuals living in neighborhoods with greater socioeconomic disadvantage had lower mean LE8 scores (i.e., worse CVH) compared with those living in neighborhoods with lesser disadvantage (T1 vs. T2 adjusted mean: 82.6 vs. 80.5; adj. ß:2.08; 95 % CI:3.51, -0.64; and T1 vs. T3 adjusted mean: 82.6 vs. 77.8; adj. ß:4.77; 95 % CI:8.16, -1.38). Neighborhood-level socioeconomic disadvantage was associated with worse maternal CVH in early pregnancy.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100925"},"PeriodicalIF":4.3,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A good night's rest: A contemporary review of sleep and cardiovascular health","authors":"Krunal D. Amin ,&nbsp;Aarti Thakkar ,&nbsp;Tara Budampati ,&nbsp;Sarina Matai ,&nbsp;Esra Akkaya ,&nbsp;Nishant P. Shah","doi":"10.1016/j.ajpc.2024.100924","DOIUrl":"10.1016/j.ajpc.2024.100924","url":null,"abstract":"<div><div>Sleep is increasingly recognized as a significant contributor to the development of cardiovascular disease (CVD). Recent American Heart Association guidelines incorporate sleep duration into the “Life's Essential Eight” framework of ideal cardiovascular health. This article will review the evidence relating sleep duration, regularity, and quality with all-cause and cardiovascular mortality, cardiometabolic syndrome, and coronary artery disease in adults. Short sleep duration is strongly associated with cardiovascular mortality, cardiometabolic risk factors, and coronary artery disease. Limited studies also suggest a possible U-shaped association, with long sleep duration also associated with greater cardiovascular risk. Sleep regularity has emerged as a strong and independent risk factor for CVD-related mortality, cardiometabolic syndrome, and subclinical atherosclerosis. Less is known about the impact of sleep quality on CVD, though a number of observational studies suggest a possible association with metabolic syndrome and subclinical atherosclerosis. This review provides an update of the literature on the cardiovascular impact of sleep for the everyday clinician and highlights gaps in knowledge that warrant future research.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100924"},"PeriodicalIF":4.3,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond secondary prevention drugs: Added benefit in survival and events of a healthy lifestyle in patients after an acute coronary syndrome","authors":"Ester Cánovas Rodríguez ,&nbsp;Andrea Kallmeyer ,&nbsp;Nieves Tarín ,&nbsp;Carmen Cristóbal ,&nbsp;Ana Huelmos ,&nbsp;Ana María Pello Lázaro ,&nbsp;Álvaro Aceña ,&nbsp;Carlos Gutiérrez-Landaluce ,&nbsp;Óscar González-Lorenzo ,&nbsp;Jairo Lumpuy-Castillo ,&nbsp;Joaquín Alonso ,&nbsp;Lorenzo López-Bescós ,&nbsp;Jesús Egido ,&nbsp;Óscar Lorenzo ,&nbsp;Luis M. Blanco-Colio ,&nbsp;José Tuñón","doi":"10.1016/j.ajpc.2024.100923","DOIUrl":"10.1016/j.ajpc.2024.100923","url":null,"abstract":"<div><h3>Objective</h3><div>To quantify the added clinical benefit of a healthy lifestyle following an acute coronary syndrome (ACS). Our study seeks to answer the question: Is adherence to medical therapy sufficient or a healthy lifestyle provides additional improvement?.</div></div><div><h3>Methods</h3><div>This is a prospective observational multi-center study of 685 ACS patients. At 6 months patients were asked about their post-ACS lifestyle and were given a score (range: 0–7) with the following items: Intake of ≥3 fruits and vegetables/day, ≥2 fish servings/week, ≤7 alcohol beverages/week, feeling stress &lt;once/month, moderate-intense physical activity in leisure time, walking at work, and giving up tobacco. One point was assigned for each of these items. Mean follow-up was 4.89 (2.85–7.70) years.</div></div><div><h3>Results</h3><div>After adjusting for demographic variables, cardiovascular risk factors, characteristics of the index event, high-sensitivity C-reactive protein (hs-CRP), and drug therapy, multivariate Cox regression showed that the lifestyle SCORE was independently and inversely associated with both the incidence of the primary outcome (ischemic events [any ACS, stroke, or Transient Ischemic Attack] or death) (HR 0.65 (CI95 % 0.44–0.96); <em>p</em> = 0.029) and death (HR 0.41 [95 %CI 0.18–0.91]; <em>p</em> = 0.029). Statin therapy was also independently and inversely associated with the incidence of the primary outcome and death. Kaplan-Meier curves showed a higher event-free survival for both outcomes in patients with SCORE≥4 (healthy lifestyle) than in those with SCORE&lt;4 (unhealthy lifestyle). Additionally, patients with a SCORE≥4 had a significantly greater decrease of total cholesterol and hs-CRP. For each 1-point increase in the score, there was a 35 % reduction in the incidence of the primary outcome (ischemic events or death) and a 59 % reduction in the incidence of death.</div></div><div><h3>Conclusion</h3><div>Among patients with ACS and similar medical therapy, a healthy lifestyle is an independent and added marker of a lower incidence of new ischemic events and death. It is also associated with a better lipid profile and lower inflammation after the ACS. As the prognosis of ACS has improved over the years due to better therapies; this study shows that lifestyle modifications continue to offer significant benefit at this point in time.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100923"},"PeriodicalIF":4.3,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cvMOBIUS2 registry","authors":"Satoshi Shoji ,&nbsp;Nishant P. Shah ,&nbsp;Peter Shrader ,&nbsp;Laine E. Thomas ,&nbsp;Jonathan D. Arnold ,&nbsp;Nafeesa N. Dhalwani ,&nbsp;Neena A. Thomas ,&nbsp;Bethany Kalich ,&nbsp;Elisa L. Priest ,&nbsp;Mahanaz Syed ,&nbsp;Cezary Wójcik ,&nbsp;Eric D. Peterson ,&nbsp;Ann Marie Navar","doi":"10.1016/j.ajpc.2024.100921","DOIUrl":"10.1016/j.ajpc.2024.100921","url":null,"abstract":"<div><h3>Objective</h3><div>Lowering lipid to reach guideline-indicated goals significantly reduces cardiovascular outcomes in very-high-risk (VHR) patients with atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes (DM2). How well VHR patients currently achieve these goals in community practice is unknown.</div></div><div><h3>Methods</h3><div>VHR patients with ASCVD and DM2 were identified across 14 US healthcare systems using electronic health records between 1/1/2021–12/31/2022. Achievement of guideline-based lipid goals was determined according to the 2018 AHA/ACC/Multisociety guideline, defined as either having a low-density lipoprotein-cholesterol &lt;70 mg/dL or receiving maximal lipid-lowering therapy (i.e., on a PCSK9i monoclonal antibody). Multivariable logistic regression was used to evaluate factors associated with the achievement of these goals.</div></div><div><h3>Results</h3><div>Among 213,380 eligible patients (median age 71.0 years, 42 % women), 51.8 % achieved guideline-based lipid goals. Female sex (odds ratio [OR], 0.64; 95 % confidence interval [CI], 0.61–0.66), Black race (OR, 0.67; 95 % CI, 0.63–0.72 vs white race), and those on Medicaid (OR, 0.92; 95 % CI, 0.86–0.97 vs Medicare) were associated with a lower likelihood of achieving guideline-based lipid goals. Overall, 76.0 % of patients were on statin, 40.5 % were on a high-intensity statin and only 5.8 % were on a statin in combination with ezetimibe or a PCSK9i monoclonal antibody.</div></div><div><h3>Conclusion</h3><div>Almost half of all VHR patients with ASCVD and DM2 do not achieve current guideline lipid goals. Women, Black individuals, and those on Medicaid were significantly less likely to achieve these goals relative to their counterparts. Further targeted quality improvement interventions are needed to improve the equitable achievement of guideline-based lipid goals.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100921"},"PeriodicalIF":4.3,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Abstracts from the ASPC 2024 congress on CVD prevention”","authors":"","doi":"10.1016/j.ajpc.2024.100898","DOIUrl":"10.1016/j.ajpc.2024.100898","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100898"},"PeriodicalIF":4.3,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary albumin-to-creatinine ratio as an independent predictor of long-term mortality in atherosclerotic cardiovascular disease patients: A propensity score-matched study","authors":"Houyong Zhu ,&nbsp;Chao Yang ,&nbsp;Xiao Liu ,&nbsp;Xiaoqun Xu ,&nbsp;Qilan Chen ,&nbsp;Xiaojiang Fang ,&nbsp;Jinyu Huang ,&nbsp;Tielong Chen","doi":"10.1016/j.ajpc.2024.100920","DOIUrl":"10.1016/j.ajpc.2024.100920","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality, and while the association between the urinary albumin-to-creatinine ratio (UACR) and cardiovascular risk is recognized, the specific impact of UACR on the long-term survival of ASCVD patients remains not fully understood. The aim of this study is to investigate the influence of UACR on the long-term risk of all-cause mortality in patients with ASCVD.</div></div><div><h3>Methods</h3><div>This study included ASCVD patients from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018. Mortality outcomes were ascertained by linkage to the National Death Index as of December 31, 2019. UACR risk was stratified into three levels: Group 0 (UACR &lt; 30 mg/g), Group 1 (30–300 mg/g), and Group 2 (&gt;300 mg/g). The primary outcome was all-cause mortality, with cardiovascular mortality as a secondary outcome. Cox proportional hazards, adjusted for demographic factors, traditional cardiovascular risk factors, and secondary prevention medications for ASCVD, were used to analyze the cumulative risk of outcomes. Propensity score matching was employed for risk adjustment, and sensitivity analyses were conducted based on cohorts with chronic coronary syndrome (CCS), stroke, heart failure, and non-heart failure.</div></div><div><h3>Results</h3><div>Among the 1,737 patients with a median follow-up of 10 years, 1,026 all-cause deaths and 351 cardiovascular deaths were recorded. After full model adjustment, higher UACR levels were associated with increased risks of all-cause mortality (Group 1: hazard ratio (HR), 1.601; 95 % confidence interval (CI), 1.382–1.855; Group 2: HR, 2.378; 95 % CI, 1.884–3.001; both <em>P</em> &lt; 0.001 for trend) and cardiovascular mortality (Group 1: HR, 2.080; 95 % CI, 1.631–2.652; Group 2: HR, 2.883; 95 % CI, 1.951–4.260; both <em>P</em> &lt; 0.001 for trend). Propensity score matching confirmed these findings, showing significantly elevated all-cause mortality risks in high-risk UACR groups (with a cutoff of 30 mg/g: HR, 1.468 (95 %CI, 1.254–1.719), <em>P</em> &lt; 0.001; with a cutoff of 300 mg/g: HR, 1.935 (95 %CI, 1.399–2.675), <em>P</em> &lt; 0.001). All sensitivity analyses were consistent with the results of the overall cohort.</div></div><div><h3>Conclusion</h3><div>UACR is an important prognostic indicator for predicting the long-term outcomes of ASCVD patients, with its impact being independent of eGFR.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100920"},"PeriodicalIF":4.3,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"American society for preventive cardiology 2024 cardiovascular disease prevention: Highlights and key sessions","authors":"Akhil A. Chandra ,&nbsp;Carlos Espiche ,&nbsp;Maisha Maliha ,&nbsp;Salim S Virani ,&nbsp;Roger S Blumenthal ,&nbsp;Fatima Rodriguez ,&nbsp;Nathan D Wong ,&nbsp;Martha Gulati ,&nbsp;Leandro Slipczuk ,&nbsp;Michael D Shapiro","doi":"10.1016/j.ajpc.2024.100919","DOIUrl":"10.1016/j.ajpc.2024.100919","url":null,"abstract":"<div><div>Groundbreaking strategies for preventive cardiology were showcased at the 2024 American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention held in Salt Lake City, Utah, from August 2nd to 4th, 2024. The event featured 69 moderators and 13 scientific sessions comprised of 98 topics, 36 satellite events, 133 poster presentations, and 27 lifestyle classes.</div><div>The conference highlighted innovative strategies focused on integrating cardiovascular, kidney, and metabolic health, presenting a cohesive approach for managing complex, interrelated conditions. Pivotal studies have addressed the role of lipid-lowering therapies, the benefits of early statin initiation, and the importance of precision medicine in preventing CVD.</div><div>The ASPC's emphasis on translating this research into practical clinical tools has the potential to revolutionize preventive care strategies, making strides toward reducing the burden of CVD globally and improving long-term patient outcomes through personalized and early intervention approaches.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100919"},"PeriodicalIF":4.3,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular ageing manifestations and hypertension in the community","authors":"Guillermo A. Alanis ,&nbsp;Pierre Boutouyrie ,&nbsp;Mouad Abouqateb ,&nbsp;Rosa Maria Bruno ,&nbsp;Rachel E. Climie ,&nbsp;Thomas van Sloten ,&nbsp;Nicolas Danchin ,&nbsp;Bruno Pannier ,&nbsp;Stéphane Laurent ,&nbsp;Xavier Jouven ,&nbsp;Jean-Philippe Empana","doi":"10.1016/j.ajpc.2024.100918","DOIUrl":"10.1016/j.ajpc.2024.100918","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the association between joint manifestations of vascular ageing (VA) and hypertension.</div></div><div><h3>Methods</h3><div>We used baseline (2008–2012) and follow-up data (up to 2024) from the Paris Prospective Study III, a French cohort of 10,157 participants. Prevalent and incident hypertension were determined at baseline (blood pressure ≥140/90 mmHg or on medication) and at 2, 4, 6, 8 and 10 years of follow-up (self-reported antihypertensive treatment). VA manifestations were assessed at baseline via echo-tracking in the right common carotid artery. Clustering analysis identified patterns of VA and their association with hypertension was assessed with logistic regression.</div></div><div><h3>Results</h3><div>The cross-sectional analysis included 9,096 participants (mean age: 59±6 years, 39 % female). Hypertension prevalence was 36 % (<em>n</em> = 3,276). Three clusters of VA manifestations were identified. Cluster 1 (<em>n</em> = 4,326;47.6 %) was characterized by healthy vascular ageing (HVA), Cluster 2 by increased arteriosclerosis (ART) (<em>n</em> = 2,274;25.0 %) and Cluster 3 by greater atherosclerosis prevalence (ATH) (<em>n</em> = 2,496;27.4 %). Compared to the HVA cluster, ART (aOR 3.94; 95 % CI 3.50;4.45) and ATH clusters (aOR 2.69; 95 % CI 2.38;3.04) were associated with prevalent hypertension. The prospective analysis included 5,310 normotensives with 754 (14.1 %) cases of incident hypertension (median follow-up of 10.05 years [range: 10.00;10.15]). Both ART (aOR 1.34; 95 % CI 1.08;1.65) and ATH (aOR 1.70; 95 % CI 1.40;2.07) clusters were associated with incident hypertension.</div></div><div><h3>Conclusion</h3><div>Vascular ageing manifestations reflecting increased carotid arteriosclerosis and atherosclerosis are related to prevalent and incident hypertension.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100918"},"PeriodicalIF":4.3,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital Health Interventions for the Optimization of Postpartum Cardiovascular Health: A Systematic Scoping Review","authors":"Anaïs Hausvater ,&nbsp;Mitchell Pleasure ,&nbsp;Dorice Vieira ,&nbsp;Darcy Banco ,&nbsp;John A. Dodson","doi":"10.1016/j.ajpc.2024.100917","DOIUrl":"10.1016/j.ajpc.2024.100917","url":null,"abstract":"<div><h3>Background</h3><div>Digital health technologies have been proposed as a potential solution to improving maternal cardiovascular (CV) health in the postpartum (PP) period. In this context we performed a systematic scoping review of digital health interventions designed to improve PP CV health.</div></div><div><h3>Methods</h3><div>We conducted a systematic review of PubMed/MEDLINE, EMBASE, CINAHL, Web of Science and the Cochrane Library. We included studies of PP women, with an intervention involving digital or mobile health (wearable devices, telemedicine, or remote monitoring). We included studies that measured an outcome related to CV health.</div></div><div><h3>Results</h3><div>110 full studies were reviewed for eligibility and 38 were included. Studies were categorized into 4 broad CV outcomes: blood pressure (BP), physical activity (PA), diet/weight loss and cardiometabolic markers. Digital health interventions included mobile applications, text-based coaching, interactive websites, virtual reality, wearable devices. The majority of remote BP monitoring programs (<em>N</em> = 5 studies) were successful in optimizing BP. 14 studies examined interventions aimed at improving PA levels of which 6/14 studies showed modest benefit at increasing PA. The majority of interventions aimed at weight loss (<em>N</em> = 27 studies) showed no significant benefit in terms of lowered caloric intake and/or weight loss up to 1 year PP. 6 studies examined improvements in cardiometabolic markers such as lipids and glucose levels, of which the majority showed no benefit.</div></div><div><h3>Conclusion</h3><div>The majority of studies we reviewed found that digital health interventions such as mobile health, telemonitoring and wearable devices were feasible and had mixed effectiveness in improving postpartum CV health in the postpartum period.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100917"},"PeriodicalIF":4.3,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}